Top

International Journal of Clinical Oncology

Published in:

Open Access 01-06-2018 | Original Article

Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands

Authors: Johannes J. M. Kwakman, G. Vink, J. H. Vestjens, L. V. Beerepoot, J. W. de Groot, R. L. Jansen, F. L. Opdam, H. Boot, G. J. Creemers, J. M. van Rooijen, M. Los, A. J. E. Vulink, H. Schut, E. van Meerten, A. Baars, P. Hamberg, E. Kapiteijn, D. W. Sommeijer, C. J. A. Punt, M. Koopman

Published in: International Journal of Clinical Oncology | Issue 3/2018

Abstract

Background

The RECOURSE trial showed clinical efficacy for trifluridine/tipiracil for refractory metastatic colorectal cancer patients. We assessed the feasibility and effectiveness of trifluridine/tipiracil in daily clinical practice in The Netherlands.

Methods

Medical records of patients from 17 centers treated in the trifluridine/tipiracil compassionate use program were reviewed and checked for RECOURSE eligibility criteria. Baseline characteristics, safety, and survival times were compared, and prespecified baseline characteristics were tested in multivariate analyses for prognostic significance on overall survival (OS).

Results

A total of 136 patients with a median age of 62 years were analyzed. Forty-three patients (32%) did not meet the RECOURSE eligibility criteria for not having received all prior standard treatments (n = 35, 26%) and/or ECOG performance status (PS) 2 (n = 12, 9%). The most common grade ≥3 toxicities were neutropenia (n = 44, 32%), leukopenia (n = 8, 6%), anemia (n = 7, 5%), and fatigue (n = 7, 5%). Median progression-free survival (PFS) and median OS were 2.1 (95% CI, 1.8–2.3) and 5.4 months (95% CI, 4.0–6.9), respectively. Patients with ECOG PS 2 had a worse median OS (3.2 months) compared to patients with ECOG PS 0–1 (5.9 months). ECOG PS, KRAS-mutation status, white blood cell count, serum lactate dehydrogenase, and alkaline phosphatase were prognostic factors for OS.

Conclusions

Our data show that treatment with trifluridine/tipiracil in daily clinical practice is feasible and safe. Differences in patient characteristics between our population and the RECOURSE study population should be taken into account in the interpretation of survival data. Our results argue against the use of trifluridine/tipiracil in patients with ECOG PS 2.

Funding

Johannes J.M. Kwakman received an unrestricted research grant from Servier.

Mayer RJ, Van Cutsem E, Falcone A et al (2015) Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372(20):1909–1919CrossRefPubMed

Tanaka N, Sakamoto K, Okabe H et al (2014) Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models. Oncol Rep 32(6):2319–2326CrossRefPubMedPubMedCentral

Emura T, Suzuki N, Fujioka A et al (2005) Potentiation of the antitumor activity of alpha, alpha, alpha-trifluorothymidine by the co-administration of an inhibitor of thymidine phosphorylase at a suitable molar ratio in vivo. Int J Oncol 27(2):449–455PubMed

Fukushima M, Suzuki N, Emura T et al (2000) Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2′-deoxyribonucleosides. Biochem Pharmacol 59(10):1227–1236CrossRefPubMed

Longo-Muñoz F, Argiles G, Tabernero J et al (2017) Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial. Clin Transl Oncol 19(2):227–235CrossRefPubMed

Haller DG, Cassidy J, Clarke SJ et al (2008) Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 26(13):2118–2123CrossRefPubMed

Kwakman JJ, Punt CJ (2016) Oral drugs in the treatment of metastatic colorectal cancer. Expert Opin Pharmacother 17(10):1351–1361CrossRefPubMed

Mol L, Ottevanger PB, Koopman M et al (2016) The prognostic value of WHO performance status in relation to quality of life in advanced colorectal cancer patients. Eur J Cancer 66:138–143CrossRefPubMed

Köhne CH, Cunningham D, Di Costanzo F et al (2002) Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 13(2):308–317CrossRefPubMed

10.

Pietrantonio F, Miceli R, Rimassa L et al (2017) Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram. Ann Oncol 28(3):555–561PubMed

11.

Kasi PM, Kotani D, Cecchini M et al (2016) Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study. BMC Cancer 16:467CrossRefPubMedPubMedCentral

12.

Hamauchi S, Yamazaki K, Masuishi T et al (2017) Neutropenia as a predictive factor in metastatic colorectal cancer treated with TAS-102. Clin Colorectal Cancer 16(1):51–57CrossRefPubMed

13.

Suenaga M, Schirripa M, Cao S et al (2017) Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer. Ann Oncol 28(5):1015–1022CrossRefPubMedPubMedCentral

14.

Prigerson HG, Bao Y, Shah MA et al (2015) Chemotherapy use, performance status, and quality of life at the end of life. JAMA Oncol 1(6):778–784CrossRefPubMedPubMedCentral

15.

Punt CJ, Koopman M, Vermeulen L (2017) From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nat Rev Clin Oncol 14(4):235–246CrossRefPubMed

16.

Brulé SY, Jonker DJ, Karapetis CS et al (2015) Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. Eur J Cancer 51(11):1405–1414CrossRefPubMed

Title: Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands
Authors: Johannes J. M. Kwakman
G. Vink
J. H. Vestjens
L. V. Beerepoot
J. W. de Groot
R. L. Jansen
F. L. Opdam
H. Boot
G. J. Creemers
J. M. van Rooijen
M. Los
A. J. E. Vulink
H. Schut
E. van Meerten
A. Baars
P. Hamberg
E. Kapiteijn
D. W. Sommeijer
C. J. A. Punt
M. Koopman
Publication date: 01-06-2018
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 3/2018
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-017-1220-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Funding

Please log in to get access to this content

Other articles of this Issue 3/2018

Effect of postoperative radiotherapy on survival in duodenal adenocarcinoma: a propensity score-adjusted analysis of Surveillance, Epidemiology, and End Results database

Prognostic factors in Chinese patients with prostate cancer receiving primary androgen deprivation therapy: validation of Japan Cancer of the Prostate Risk Assessment (J-CAPRA) score and impacts of pre-existing obesity and diabetes mellitus

Lymphatic vessel involvement is predictive for lymph node metastasis and an important prognostic factor in endometrial cancer

Phase I study of primary treatment with 5-FU, oxaliplatin, irinotecan, levofolinate, and panitumumab combination chemotherapy in patients with advanced/recurrent colorectal cancer involving the wild-type RAS gene: the JACCRO CC-14 study

Characteristics of MUTYH variants in Japanese colorectal polyposis patients

A comparison of the prognosis between adenocarcinoma and squamous cell carcinoma in stage IB–IIA cervical cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer